Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AZ, Pfizer Enter into Agreement for OTC Nexium, Also Eyeing OTC Versions of Other AZ Products
August 16, 2012
- Additional Indication of Pancreatic Neuroendocrine Tumors Approved for Sutent: Pfizer
August 16, 2012
- Symbicort Approved for COPD: Astellas, AZ
August 16, 2012
- Sosei Discontinues Development of Neuropathic Pain Treatment SD118, Transfers Rights to Beijing Tide of China
August 16, 2012
- MRs Ranks 3rd in Number of Average Annual Holidays at 133 Days: Survey
August 15, 2012
- Otsuka HD to Discuss with FDA this Month Delay in Approving Aripiprazole Injection
August 15, 2012
- Differences in Concurrent-Use Indications for DPP-4 Inhibitors to Be Eliminated through Special Clinical Trials
August 15, 2012
- Seikagaku Wins US Patent Suit over Joint Function Improver
August 15, 2012
- Nichi-Iko to Shift to 2-Headquarters System in Oct.
August 15, 2012
- Otsuka HD’s April-June Pharma Sales Up 2.7% Despite Decline in Abilify Sales
August 15, 2012
- RaQualia Representative Director Nagahisa Steps Down, Mr Tani Appointed New Representative Director
August 15, 2012
- Over 20% of Doctors Report Decline in Meetings with MRs Since Revision of Business Entertainment GLs in April: CareNet Survey
August 13, 2012
- Business Strategies of Generics Manufacturers Become Evident Ahead of Upcoming Round of Patent Expiries
August 13, 2012
- Asahi Kasei in Hot Pursuit of Eli Lilly Japan as Competition Heats Up in Market for Bone Formation Agents
August 13, 2012
- Astellas Concludes Marketing Agreement with Nippon Kayaku for Vascular Embolization Material
August 10, 2012
- Takeda Terminates PIII Trial for AMG 479 for Pancreatic Cancer in Japan
August 10, 2012
- Up to 50% of Doctors Know About “Established Products” as Recognition Levels Rise: Pfizer Survey
August 9, 2012
- Mylan Transfers Exclusive Rights to Pfizer to Market EpiPen in Japan
August 9, 2012
- Shionogi’s Korean Partner Obtains Approval for Pirespa
August 9, 2012
- Astellas Applies for Irribow OD Tablet
August 9, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…